Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.
Details : The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-t...
Product Name : Intrarosa
Product Type : Hormone
Upfront Cash : Undisclosed
August 06, 2023
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Theramex
Deal Size : Undisclosed
Deal Type : Partnership
Details : Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
Product Name : Intrarosa
Product Type : Hormone
Upfront Cash : Undisclosed
February 14, 2022
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Theramex
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Recipient : Center for Vulvovaginal Disorders
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 20, 2018
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Recipient : Center for Vulvovaginal Disorders
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasterone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 14, 2018
Lead Product(s) : Prasterone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 07, 2018
Lead Product(s) : Prasterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : AMAG Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 19, 2017
Lead Product(s) : Prasterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Prasterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical DHEA Against Vaginal Atrophy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2013
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2011
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2011
Lead Product(s) : Dehydroepiandrosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
